Abstract
Purpose In this prospective exploratory study, we evaluated the feasibility of [F-18]fluorodeoxyglucose ([F-18]FDG) PET/MRI-based chemotherapy response prediction in pancreatic ductal adenocarcinoma at two weeks upon therapy onset. Material and methods In a mixed cohort, seventeen patients treated with chemotherapy in neoadjuvant or palliative intent were enrolled. All patients were imaged by [F-18]FDG PET/MRI before and two weeks after onset of chemotherapy. Response per RECIST1.1 was then assessed at 3 months [F-18]FDG PET/MRI-derived parameters (MTV50%, TLG(50%), MTV2.5, TLG(2.5), SUVmax, SUVpeak, ADC(max), ADC(mean) and ADC(min)) were assessed, using multiple t-test, Man-Whitney-U test and Fisher's exact test for binary features. Results At 72 +/- 43 days, twelve patients were classified as responders and five patients as non-responders. An increase in increment MTV50% and increment ADC (>= 20% and 15%, respectively) and a decrease in increment TLG(50%) (<= 20%) at 2 weeks after chemotherapy onset enabled prediction of responders and non-responders, respectively. Parameter combinations ( increment TLG(50%) and increment ADC(max) or increment MTV50% and increment ADC(max)) further improved discrimination. Conclusion Multiparametric [F-18]FDG PET/MRI-derived parameters, in particular indicators of a change in tumor glycolysis and cellularity, may enable very early chemotherapy response prediction. Further prospective studies in larger patient cohorts are recommended to their clinical impact.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
ISSN: | 2191-219X |
Sprache: | Englisch |
Dokumenten ID: | 98762 |
Datum der Veröffentlichung auf Open Access LMU: | 05. Jun. 2023, 15:29 |
Letzte Änderungen: | 17. Okt. 2023, 14:59 |